Here is something positive for some of you who couldnt attend the meeting - my notes from the meeting on DEP (may or may not be quite accurate) reflect :
Starpharma's DEP hopes to "reshape the future of oncology".
Their strategy of targeting heavily pretreated patients i.e who have failed all other treatments, helps in submissions to Regulators for rapid entry to markets for those cohorts of patients currently being poorly served. Such trials need only be small in number of participants with good outcomes, to present convincing arguments to the Regulator.
There is plenty of evidence that DEP has been shown to improve the therapeutic index of drugs.
Partnership discussions are happening now across a number of DEP areas.
AZD0466 is exciting as its was originally a highly toxic drug - DEP improved its therapeutic index 20 fold.
Finally I thought all statements and responses by Management to questions about DEP (internal and external) were fair and reasonable.
As always do your own research, and be careful of people with beliefs that may never change whatever the facts.
SPL Price at posting:
51.0¢ Sentiment: Buy Disclosure: Held
